Literature DB >> 15568037

Accidental busulfan overdose during conditioning for stem cell transplantation.

A Jenke1, J Freiberg-Richter, S Wilhelm, M Freund, U D Renner, M Bornhäuser, E Schleyer, G Ehninger, U Schuler.   

Abstract

High dose busulfan is widely used in preparative regimens for bone marrow transplantation. We describe three cases of accidental busulfan overdosing. Two adults received a single dose of 8 and 18 mg/kg busulfan, respectively. Doses of 9 x 4 mg/kg were ingested by a 14-year-old girl, who experienced seizures. In all cases, no severe liver toxicity including veno-occlusive disease was observed. Plasma samples were obtained from two patients. Busulfan plasma concentrations were far above published values after high-dose busulfan treatment. Busulfan was eliminated by a first-order process. All patients survived these high doses of busulfan and successful transplantation was possible. Two patients died from refractory GvHD on days 91 and 80 after transplantation. One patient is alive in remission after an observation time of 18 months. These cases show that busulfan overdosing may occur and pharmacokinetic evaluation is warranted to estimate risk of early and late toxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15568037     DOI: 10.1038/sj.bmt.1704697

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

Review 1.  Hepatobiliary complications of hematopoietic cell transplantation, 40 years on.

Authors:  George B McDonald
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

2.  Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.

Authors:  Andrew R Rezvani; Jeannine S McCune; Barry E Storer; Ami Batchelder; Aiko Kida; H Joachim Deeg; George B McDonald
Journal:  Biol Blood Marrow Transplant       Date:  2013-04-10       Impact factor: 5.742

3.  Subacute hepatic necrosis mimicking veno-occlusive disease in a patient with HFE H63D homozygosity after allogeneic hematopoietic cell transplantation with busulfan conditioning.

Authors:  Sylvia Chen; James Dane Osborn; Xinjian Chen; Michael W Boyer; George B McDonald; Gerhard Carl Hildebrandt
Journal:  Int J Hematol       Date:  2015-12       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.